Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CLDI

Calidi Biotherapeutics Inc

Oct 04 • 02:01PM ET

1.03

Dollar change -0.05
Percentage change -4.63	%

Healthcare • Biotechnology • USA • AMEX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-7.16	Insider Own	23.18%	Shs Outstand	8.08M	Perf Week	-14.88%
Market Cap	8.32M	Forward P/E	-	EPS next Y	-0.91	Insider Trans	0.00%	Shs Float	6.21M	Perf Month	-9.65%
Income	-24.92M	PEG	-	EPS next Q	-0.86	Inst Own	14.40%	Short Float	4.54%	Perf Quarter	-36.46%
Sales	0.00M	P/S	-	EPS this Y	77.06%	Inst Trans	-98.37%	Short Ratio	1.38	Perf Half Y	-74.00%
Book/sh	-1.82	P/B	-	EPS next Y	77.15%	ROA	-92.17%	Short Interest	0.28M	Perf Year	-96.16%
Cash/sh	0.12	P/C	8.85	EPS next 5Y	-	ROE	-238.50%	52W Range	1.01 - 33.20	Perf YTD	-93.18%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-96.90%	Beta	0.59
Dividend TTM	-	Quick Ratio	0.12	Sales past 5Y	-50.00%	Gross Margin	-	52W Low	1.98%	ATR (14)	0.09
Dividend Ex-Date	-	Current Ratio	0.12	EPS Y/Y TTM	20.50%	Oper. Margin	0.00%	RSI (14)	34.29	Volatility	8.46% 6.39%
Employees	41	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.50	Target Price	6.25
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	67.69%	Payout	-	Rel Volume	0.23	Prev Close	1.08
Sales Surprise	-	EPS Surprise	3.45%	Sales Q/Q	-	Earnings	Aug 13 AMC	Avg Volume	204.56K	Price	1.03
SMA20	-10.08%	SMA50	-22.75%	SMA200	-77.88%	Trades		Volume	35,212	Change	-4.63%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-22-23	Initiated	H.C. Wainwright	Buy	$11
Oct-09-23	Initiated	Robert W. Baird	Outperform	$9

Sep-30-24 08:00AM	Calidi Biotherapeutics Announces FDA Clearance of the Northwestern University IND Application for CLD-101 Clinical Trial in High-Grade Glioma (GlobeNewswire) -5.79%
Aug-13-24 05:37PM	Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results (GlobeNewswire) -5.71%
Aug-02-24 09:00AM	GreenPower Motor and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE) -8.38%
Jul-29-24 09:00AM	Calidi Biotherapeutics Announces Launch of Nova Cell Subsidiary and $3 Million Aggregate Investment from Dr. Ronald Rigor (GlobeNewswire)
Jul-18-24 08:00AM	Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform (GlobeNewswire) -8.43%
08:00AM	Loading…
Jul-16-24 08:00AM	Calidi Biotherapeutics Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board (GlobeNewswire) +7.42%
Jul-05-24 04:15PM	Calidi to Effect Reverse Stock Split (Business Wire) -18.30%
Jun-27-24 07:00AM	Calidi Biotherapeutics Announces Appointment of Cancer Immunotherapy Pioneer Dr. George Peoples to Board of Directors (Business Wire)
Jun-11-24 04:05PM	Calidi Biotherapeutics to Host Exclusive Live Investor Webinar and Q&A Session on June 13 (Business Wire) +31.71% -16.67%
Jun-10-24 07:00AM	Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidis Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors (Business Wire) +6.22%
Jun-03-24 07:00AM	Calidi Biotherapeutics Presents CLD-101 Phase 1 Trial Update and Preclinical Data Highlighting RTNova and CLD-201 at 2024 ASCO Annual Meeting (Business Wire) +15.79%
May-31-24 08:51AM	Calidi Biotherapeutics Announces Exercise of Warrants for $2.1 Million Gross Proceeds (Business Wire) -36.67%
May-24-24 09:00AM	ASP Isotopes and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
May-17-24 09:00AM	Calidi Biotherapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Mone(TM) Show on Bloomberg TV (ACCESSWIRE) -5.99%
May-14-24 04:05PM	Calidi Biotherapeutics Reports First Quarter 2024 Operating and Financial Results (Business Wire)
09:15AM	Loading…
May-07-24 09:15AM	Sidoti Events, LLC's Virtual May Micro-Cap Conference (ACCESSWIRE) +7.95%
May-01-24 07:00AM	Calidi Biotherapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting (Business Wire)
Apr-23-24 07:00AM	Join Calidi Biotherapeutics Exclusive Live Investor Webinar and Q&A Session on April 24 (Business Wire) +7.05%
Apr-19-24 04:05PM	Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering (Business Wire)
Apr-16-24 08:31AM	Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering (Business Wire) -65.48%
Apr-09-24 07:00AM	Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Companys Novel Immunotherapies at the AACR Annual Meeting 2024 (Business Wire) +62.39%
Mar-15-24 04:05PM	Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results (Business Wire) -5.81%
Mar-11-24 07:00AM	Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Cancer (Business Wire)
Feb-12-24 07:00AM	Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference (Business Wire)
Jan-08-24 07:00AM	Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board (Business Wire) +6.84%
Dec-13-23 07:00AM	Calidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the 8th Oncolytic Virotherapy Summit (Business Wire)
Dec-12-23 07:00AM	Calidi Biotherapeutics Announces Appointment of Pharmaceutical Industry Veteran David LaPré to its Board of Directors (Business Wire)
Nov-20-23 07:00AM	Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform and Updates Anticipated Clinical Milestones (Business Wire)
Nov-14-23 04:05PM	Calidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial Results (Business Wire) -6.98%
Nov-03-23 07:00AM	Calidi Biotherapeutics (NYSEAM: CLDI) Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancers 38th Annual Meeting (SITC 2023) (Business Wire) +18.90%
07:00AM	Loading…
Nov-01-23 07:00AM	Calidi Biotherapeutics Announces Key Leadership Promotions and New Board Appointment (Business Wire) -10.55%
Oct-30-23 07:00AM	Calidi Biotherapeutics Announces Appointment of Andrew Jackson as Chief Financial Officer (Business Wire) -13.19%
Oct-10-23 07:00AM	Calidi Biotherapeutics To Present New Preclinical Data Highlighting Cell-based Virotherapy (SuperNova) Platform Technology at SITC 2023 (Business Wire)
Sep-13-23 05:50AM	Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies (GlobeNewswire) -38.75%
Sep-11-23 04:05PM	First Light Acquisition Group Announces NYSE Approval for Listing of Business Combination with Calidi Biotherapeutics and Additional New Capital Commitments (GlobeNewswire) -5.66%
Aug-24-23 12:06PM	FIRST LIGHT ACQUISITION GROUP, INC. Further Adjourns Special Meeting of Stockholders to August 28, 2023 at 10:30 am ET (GlobeNewswire)
Aug-22-23 11:41AM	FIRST LIGHT ACQUISITION GROUP, INC. Adjourns Special Meeting of Stockholders to August 24, 2023 at 10:30 am ET (GlobeNewswire) -10.85%
Aug-16-23 06:00AM	Flag Stockholders: Reminder to Vote for Proposed Business Combination (GlobeNewswire)
Aug-07-23 05:00AM	First Light Acquisition Group, Inc. Announces Effectiveness of Registration Statement and Sets August 22, 2023 as Date of Stockholder Meeting for the Calidi Business Combination (GlobeNewswire)
Jun-23-23 05:00AM	Calidi Biotherapeutics Announces Commitment of $25 Million in Series B Funding to Advance Stem Cell-Based Platforms for the Delivery and Potentiation of Oncolytic Viruses to Treat Cancer (GlobeNewswire)

Calidi Biotherapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which engages in stem cell-based platforms to revolutionize oncolytic virotherapies. The company was founded in 2014 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schoeneck James A	Director	Jun 03 '24	Option Exercise	0.20	548,000	109,600	963,887	Jun 05 04:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CLDI

Calidi Biotherapeutics Inc

Upgrade your FINVIZ experience